{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'V Contraindications, including the following must be checked before infusion: severe active infection, uncontrolled hypertension, history of arterial dissection of the cervicocephalic arteries, history of stroke, history of', 'angina pectoris or myocardial infarction, known coagulopathy or on concomitant anti-coagulant therapy', '1.2.2 Schedule of events Part 2 (Year 2)', 'Table 2 - Schedule of events in Year 2', 'Visit Daya', 'M13', 'M14', 'M15', 'M16', 'M17', 'M18', 'M19', 'M20', 'M21', 'M22', 'M23', 'M24 (EOTP)', 'Relapse', 'Visit', 'Visit number', 'V17', 'V18', 'V19', 'V20', 'V21', 'V22', 'V23', 'V24', 'V25', 'V26', 'V27', 'V28', 'Treatment:', 'Efficacy:', 'EDSS', 'X', 'X', 'Brain MRI\u00b0', 'X', 'SDMT', 'X', 'BVMT-R Test', 'X', 'PedsQL (QoL Questionnaire)/', 'X', 'Ped. NeuroQoL (subcomp.) d', 'Safety:', 'Physical examination', 'X', 'X', 'X', 'Clinical chemistry laboratories\u00b9', 'X', 'Hematology (Differential CBC1', 'X', 'X', 'Thyroid Function Tests9', 'X', 'Urinalysis h', 'X', 'X', 'Serum Creatinine and alanine aminotransferase', 'X', 'Lymphocyte phenotyping', 'X', 'X', 'Samples for antibodies to Study Drug', 'Tanner Staging', 'X', 'Concommitant medications', 'AE/SAE recording (if any)', 'Vital Signs', 'X', 'HPVJ (yearly)', 'Laboratory testing:', 'PK sampling k', 'XK', 'Immune Marker Sampling (optional)', 'X', 'Abbreviations: AE: adverse event; BVMT-R: brief visuospatial memory test-revised, CBC: complete blood count; EDSS: Expanded Disability Status Scale; EOTP: end of treatment phase; M: month(s); MRI: magnetic', 'resonance imaging; Neuro-QoL: quality of life in neurological disorders; Ped: pediatric; PK: pharmacokinetics; QoL: quality of life; SAE: serious adverse event; SDMT: symbol digit modality test.', 'Property of the Sanofi Group - strictly confidential', 'VV-CLIN-0254406 5.0', 'Page 17']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'a Recommended windows: The window for obtaining samples and performing assessments at any given visit will be 7 days, except for the D-14 to D-7 visit which should occur between -7 to -1 days prior to MO/D1.', 'All post M0/D1 treatment period assessments should be completed within +7 days of the scheduled visit date relative to the M0/D1 visit.', 'b', 'This visit is only required for subjects that have a suspected relapse, and should occur within 7 days following the occurrence of the clinical event.', 'C The MRI assessments will be available to investigators to assess safety.', 'd PedsQL questionnaire (Paediatric Quality of Life Inventory) will be completed by patients/parents based on questionnaire recommendations. Peds NeuroQoL is a quality of life measurement developed for', 'neurological disorders and consists of short form questions for multiple domains. Specific sub-domains will be utilized.', \"e The date of first menarche should be captured if applicable. 'A standard physical examination for clinical and neurological assessments which includes examination of major body systems, height and body weight.\", 'f', 'Hematology and differential panel (hemoglobin, hematocrit, red blood cell count, mean corpuscular hemoglobin, white blood cell count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets)', 'Complete chemistry panel (glucose, creatinine, blood urea nitrogen (BUN), sodium, potassium, chloride, bicarbonate, magnesium, calcium uric acid, aspartate aminotransferase (AST), ALT, gamma-glutamyl', 'transpeptidase (GGT), lactate dehydrogenase (LDH), total bilirubin, direct/indirect bilirubin, alkaline phosphatase, inorganic phosphorus, total protein, albumin, globulin, albumin/globulir ratio, triglycerides,', 'cholesterol and creatine phosphokinase (CPK). It is preferred that CBCs with platelet count, and monitoring for any cytopenia as well as serum creatinine, and urinalysis with microscopy be analyzed at the central', 'laboratory, but under special circumstances (eg, if patient is unable to visit the study center weekly or monthly, or results are needed urgently), the assay may be performed at a local laboratory provided that test', 'results are entered into the e-CRF in a timely manner. However for study visits that only require laboratory sampling, home nursing or local laboratories may be used for sample collection and shipment to the', 'central laboratory, as per local regulations. These visits are to be followed by telephone calls from the study site to assess AEs and concomitant', 'medications.', 'g Thyroid stimulating hormone (TSH) & if abnormal T3 & T4 performed on the existing samples. However for study visits that only require laboratory sampling, home nursing or local laboratories may be used for', 'sample collection and shipment to the central laboratory, as per local regulations. These visits are to be followed by telephone calls from the study site to assess AEs and concomitant medications.', 'h Urinalysis (pH, ketones, cells, protein, glucose, blood, urobilinogen, bilirubin, microscopic sediment, specific gravity) However for study visits that only require laboratory sampling, home nursing or local', 'laboratories may be used for sample collection and shipment to the central laboratory, as per local regulations. These visits are to be followed by telephone calls from the study site to assess AEs and', 'concomitant medications.', 'i', 'Tanner stage to be assessed as noted until complete sexual maturity.', 'j', 'Testing will be conducted for human papillomavirus (HPV) infection as and when recommended by local public health authorities. If the testing is positive, the patient may be eligible after the condition has resolved', 'as per the Investigator opinion (eg, follow-up HPV test is negative or cervical abnormality has been effectively treated). An annual follow-up is recommended.', 'k', 'For details on PK sampling, refer to Section 1.2.5.', 'Property of the Sanofi Group - strictly confidential', 'VV-CLIN-0254406 5.0', 'Page 18']\n\n###\n\n", "completion": "END"}